ClinicalTrials.gg
CompletedNCT00688909REALUpdated Jun 9, 2021Results posted

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

A Phase 4 interventional study of letrozole in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 48 sites in United States. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
261
Allocation
Not applicable
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
39th of 159
261 · median 95
Started
2008
with 9 others
Phase 4
17 of 162
2 open now
Registered
58th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 39th largest by enrollment of the 159 interventional ones that give a count, is one of 10 that started in 2008, is one of 17 in phase 4, and was the 58th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole

Read the detailed description

This is a multi-center prospective non-randomized single arm, open label trial in postmenopausal HR positive early breast cancer patients who experience grade 2-3 arthralgia-myalgia while on anastrozole, resulting in the discontinuation of anastrozole. After a 2-3 week period without any aromatase inhibitor treatment, eligible patients will initiate letrozole treatment at a dose of 2.5mg per day for a duration of 24 weeks. If a patient has breast cancer recurrence or is intolerant to letrozole during the 24 week period, the drug will be discontinued.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • adjuvant treatment in post menopausal women
  • letrozole
  • arthralgia-myalgia
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women with HR+ early stage breast cancer at the time of initial diagnosis. For study purposes, postmenopausal is defined as:

    • Age ≥ 50 y and amenorrheic for 12 or more months.
    • Age ≥ 50 y and amenorrheic for 3 or more months after receiving chemotherapy.
    • Age \< 50 y and amenorrheic for 12 or more months.
    • Prior bilateral oophorectomy.
    • Prior hysterectomy and has postmenopausal levels of FSH, LH, and estradiol as per local institutional standards.
    • Age > 55 y and prior hysterectomy.
  2. Patients who are intolerant and discontinue anastrozole 2-3 weeks prior to study entry when given as adjuvant treatment for HR+ early stage breast cancer due to grade 2-3 ( V3) arthralgia-myalgia.
  3. Hormone receptor-positive tumors as defined by institutional standards.
  4. performance status of 0, 1, or 2
  5. Consent to participate in the trial. -

Exclusion criteria

Exclusion Criteria:

  1. women with HR+ or locally breast cancer excluding chest wall recurrence with no evidence of systemic disease.
  2. Recent history of pain associated with non-traumatic bone fracture.
  3. Pain requiring chronic use of analgesics (due to any reason).
  4. History of rheumatological disease except osteoarthritis.
  5. Prior hormonal therapy with AIs other than anastrozole.
  6. Systemic hormone replacement therapy (HRT) less than 4 weeks before study entry other than Estring®, Vagifem® or low dose estrogen vaginal cream.
  7. Concomitant disease which significantly affects quality of life.
  8. Patient unable to complete self administered questionnaire.
  9. Patients unable to sign consent form.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
261 participants (actual)

Study arms

  • Experimental
    Letrozole

    Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.

    Drug: letrozole

Interventions

  • 2.5 mg daily by mouth for 6 months

    Also known as: Femara

06

What researchers measure

Primary outcomes

  1. Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia.

    The arthralgia status and the myalgia status were separately graded at Baseline (V1), Week 12 (V3) , and Week 24/EOS (V4). The grades of 0 for no pain, 1 for mild pain, 2 for moderate pain, 3 for severe pain, and 4 for disabling pain were used.

    Time frame: End of Study (24 weeks)

Secondary outcomes

  1. Time to Discontinuation Due to Grade 2 or Higher Arthralgia- Myalgia.

    For patients who discontinued from the study due to either grade 2 or higher arthralgia-myalgia, the time to discontinuation was calculated as the duration between the Visit 1 date and the last dose date. If the last dose date was missing, the EOS date was used.

    Time frame: End of Study (24 weeks)

  2. Percentage of Participants Discontinuing, Irrespective of Cause

    The percentage of patients who discontinued from the study irrespective of the reasons.

    Time frame: End of Study (24 weeks)

  3. Change in Brief Pain Inventory (BPI) Composite Score

    The BPI is a pain assessment tool for use with cancer patients. The BPI measures both the intensity of pain (sensory dimension) and interference of pain in the patient's life (reactive dimension). It also queries the patient about pain relief, pain quality, and patient perception of the cause of pain. The BPI composite score was calculated based on questions 3 to 6 of the BPI Questionnaire (short form). First each question was scored from 0 (no pain) to 10 (pain as bad as you can imagine) and circled on the CRF. Then a composite score was calculated as the mean of the scores. If any answer was missing, the composite score was set to missing. Change in BPI composite score indicates the change from baseline at week 24.

    Time frame: Baseline, 24 weeks (End of Study)

  4. Change in Disability Index as Assessed by Health Assessment Questionnaire (HAQ)

    The HAQ is a validated, patient-oriented outcome assessment instrument. The short version '2 page HAQ' was used. It contains the HAQ Disability Index (HAQ-DI), the HAQ visual analog scale (VAS) for pain and the VAS patient global health scale. The Stanford HAQ 20-item disability scale was utilized for scoring of the Disability Index. The items were first scored within each category with values 0 to 3 (0 = Without any difficulty, 1 = With some difficulty, 2 = With much difficulty, 3 = Unable to do). The score for the disability index was the mean of the eight category scores. If more than 2 of the 8 categories, or \>25%, were missing, the scale was not scored. If ≤2 of the categories were missing, the sum of the categories was divided by the number of answered categories. Change in Disability Index indicates the change from baseline at week 24.

    Time frame: Baseline, Visit 1(24 weeks = End of Study)

  5. Change in Pain as Assessed by Visual Analog Scale (VAS) Scale of the Health Assessment Questionnaire (HAQ)

    The HAQ is a validated, patient-oriented outcome assessment instrument. The short version '2 page HAQ' was used. It contains the HAQ Disability Index (HAQ-DI), the HAQ visual analog scale (VAS) for pain and the VAS patient global health scale. The VAS is a tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain is a straight line with one end meaning no pain and the other end meaning the worst pain imaginable. For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100 \[100-mm scale\]). A higher score indicates greater pain intensity. Change in pain as assessed by VAS indicates the change from baseline at week 24.

    Time frame: Baseline, Visit 1 (24 weeks = End of Study)

07

Results

Posted May 24, 2021

Participant flow

The study enrolled 261 participants at 45 centers in United States.

Participant flow — Overall Study
MilestoneLetrozole
Started261
Completed228
Not completed33
Withdrew: Adverse event28
Withdrew: Patient withdrew consent2
Withdrew: Administrative problems1
Withdrew: Protocol violation2

Outcome measures

PrimaryNumber of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia.

The arthralgia status and the myalgia status were separately graded at Baseline (V1), Week 12 (V3) , and Week 24/EOS (V4). The grades of 0 for no pain, 1 for mild pain, 2 for moderate pain, 3 for severe pain, and 4 for disabling pain were used.

Time frame:
End of Study (24 weeks)
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia.
ParticipantsLetrozole
Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia.25
SecondaryTime to Discontinuation Due to Grade 2 or Higher Arthralgia- Myalgia.

For patients who discontinued from the study due to either grade 2 or higher arthralgia-myalgia, the time to discontinuation was calculated as the duration between the Visit 1 date and the last dose date. If the last dose date was missing, the EOS date was used.

Time frame:
End of Study (24 weeks)
Reported as:
Mean · days
Time to Discontinuation Due to Grade 2 or Higher Arthralgia- Myalgia.
daysLetrozole
Time to Discontinuation Due to Grade 2 or Higher Arthralgia- Myalgia.156.98 ± 1.94
SecondaryPercentage of Participants Discontinuing, Irrespective of Cause

The percentage of patients who discontinued from the study irrespective of the reasons.

Time frame:
End of Study (24 weeks)
Reported as:
Count of participants · Participants
Percentage of Participants Discontinuing, Irrespective of Cause
ParticipantsLetrozole
Percentage of Participants Discontinuing, Irrespective of Cause33
SecondaryChange in Brief Pain Inventory (BPI) Composite Score

The BPI is a pain assessment tool for use with cancer patients. The BPI measures both the intensity of pain (sensory dimension) and interference of pain in the patient's life (reactive dimension). It also queries the patient about pain relief, pain quality, and patient perception of the cause of pain. The BPI composite score was calculated based on questions 3 to 6 of the BPI Questionnaire (short form). First each question was scored from 0 (no pain) to 10 (pain as bad as you can imagine) and circled on the CRF. Then a composite score was calculated as the mean of the scores. If any answer was missing, the composite score was set to missing. Change in BPI composite score indicates the change from baseline at week 24.

Time frame:
Baseline, 24 weeks (End of Study)
Reported as:
Mean · score on a scale
Change in Brief Pain Inventory (BPI) Composite Score
score on a scaleLetrozole
Baseline visit2.78 ± 2.00
Week 24-0.46 ± 2.09
SecondaryChange in Disability Index as Assessed by Health Assessment Questionnaire (HAQ)

The HAQ is a validated, patient-oriented outcome assessment instrument. The short version '2 page HAQ' was used. It contains the HAQ Disability Index (HAQ-DI), the HAQ visual analog scale (VAS) for pain and the VAS patient global health scale. The Stanford HAQ 20-item disability scale was utilized for scoring of the Disability Index. The items were first scored within each category with values 0 to 3 (0 = Without any difficulty, 1 = With some difficulty, 2 = With much difficulty, 3 = Unable to do). The score for the disability index was the mean of the eight category scores. If more than 2 of the 8 categories, or \>25%, were missing, the scale was not scored. If ≤2 of the categories were missing, the sum of the categories was divided by the number of answered categories. Change in Disability Index indicates the change from baseline at week 24.

Time frame:
Baseline, Visit 1(24 weeks = End of Study)
Reported as:
Mean · score on a scale
Change in Disability Index as Assessed by Health Assessment Questionnaire (HAQ)
score on a scaleLetrozole
Visit 1 (Baseline visit)0.54 ± 0.55
Visit 4 (Week 24)-0.07 ± 0.47
SecondaryChange in Pain as Assessed by Visual Analog Scale (VAS) Scale of the Health Assessment Questionnaire (HAQ)

The HAQ is a validated, patient-oriented outcome assessment instrument. The short version '2 page HAQ' was used. It contains the HAQ Disability Index (HAQ-DI), the HAQ visual analog scale (VAS) for pain and the VAS patient global health scale. The VAS is a tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain is a straight line with one end meaning no pain and the other end meaning the worst pain imaginable. For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100 \[100-mm scale\]). A higher score indicates greater pain intensity. Change in pain as assessed by VAS indicates the change from baseline at week 24.

Time frame:
Baseline, Visit 1 (24 weeks = End of Study)
Reported as:
Mean · score on a scale
Change in Pain as Assessed by Visual Analog Scale (VAS) Scale of the Health Assessment Questionnaire (HAQ)
score on a scaleLetrozole
Visit 1 (Baseline visit)28.9 ± 24.22
Visit 4 (Week 24)-6.4 ± 29.30

Adverse events

Collected over Adverse events were collected From Start of the Study up to EOS (Week 24). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Letrozole 2.5 mg0/261 (0%)5/261 (1.9%)163/261 (62.5%)
Most frequent serious events
Most frequent serious events
EventLetrozole 2.5 mg
Cholecystitis chronicHepatobiliary disorders1/261
Post procedural bile leakInjury, poisoning and procedural complications1/261
Spinal column stenosisMusculoskeletal and connective tissue disorders1/261
DepressionPsychiatric disorders1/261
ManiaPsychiatric disorders1/261
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/261
Most frequent other events
Showing 10 of 15
Most frequent other events
EventLetrozole 2.5 mg
ArthralgiaMusculoskeletal and connective tissue disorders88/261
MyalgiaMusculoskeletal and connective tissue disorders78/261
Hot flushVascular disorders37/261
FatigueGeneral disorders32/261
NauseaGastrointestinal disorders13/261
DepressionPsychiatric disorders13/261
Oedema peripheralGeneral disorders10/261
ConstipationGastrointestinal disorders8/261
DiarrhoeaGastrointestinal disorders8/261
HeadacheNervous system disorders8/261

Baseline characteristics

Age, Continuous
Age, Continuous(years)Letrozole
Mean61.6 ± 10.2
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Letrozole
Female261
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Letrozole
Caucasian235
Black14
Asian3
Other9
Relevant Medical and Surgical History
Relevant Medical and Surgical History(Participants)Letrozole
Yes261
No0
Rheumatology History
Rheumatology History(Participants)Letrozole
Yes261
No0
08

Study locations

48 sites
  • Clearview Cancer Center
    Huntsville, Alabama 35805, United States
  • Hematology Oncology Services of Arkansas
    Little Rock, Arkansas 72205, United States
  • Grass Valley Hematology Oncology
    Grass Valley, California 95945, United States
  • Aptium Oncology - Comprehensive Cancer Care of the Desert
    Palm Springs, California 92262, United States
  • Bay Area Cancer Research Group
    Pleasant Hill, California 94523, United States
  • Front Range Specialist
    Fort Collins, Colorado 80528, United States
  • Lynn Cancer Center
    Boca Raton, Florida 33428, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • Memorial Cancer Center
    Hollywood, Florida 33021, United States
  • Palm Beach Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Northeast Georgia Cancer Care, LLC
    Athens, Georgia 30607, United States
  • Augusta Oncology
    Augusta, Georgia 30901, United States
  • Oncology Specialist of North Georgia
    Gainesville, Georgia 30501, United States
  • The Cancer Instiute at Alexian Brothers
    Elk Grove Village, Illinois 60007, United States
  • Evanston Northwestern Hospital
    Evanston, Illinois 60201, United States
  • Edward H. Kaplan MD & Associates - North Shore Cancer Research Associates
    Skokie, Illinois 60076, United States
  • Cancer Care of Kansas
    Wichita, Kansas 67214, United States
  • Kentuckiana Cancer Institute
    Louisville, Kentucky 40202, United States
  • Mercy Hospital
    Portland, Maine 04101, United States
  • Mercey Hospital
    Baltimore, Maryland 21202, United States
  • Maryland Hematology Oncology Associates, PA
    Baltimore, Maryland 21237, United States
  • Suburban Hospital Cancer Program
    Bethesda, Maryland 20817, United States
  • Hematology Oncology Asssociates of Ohio & Michigan
    Lambertville, Michigan 48144, United States
  • Center for Cancer Care and Research
    Saint Louis, Missouri 63141, United States
  • Ballas Cancer Center, LLC DBA - St Louis
    Saint Louis, Missouri 63414, United States
  • Southeast Nebraska Hematology & Oncology Consultants
    Lincoln, Nebraska 68516, United States
  • Trinitas Comprehensive Cancer Center
    Elizabeth, New Jersey 07207, United States
  • Hematology-Oncology Assoc of Northern New Jersey
    Morristown, New Jersey 07962, United States
  • Somerset Hematology & Oncology
    Somerville, New Jersey 08876, United States
  • Cooper University Hospital
    Voorhees, New Jersey 08043, United States
  • Broom Oncology
    Binghamton, New York 13905, United States
  • Cancer Care of W. NC
    Asheville, North Carolina 28801, United States
  • Marion L. Shepard Cancer Center
    Washington, North Carolina 27889, United States
  • Summa Health System
    Akron, Ohio 44304, United States
  • Mukesh Bhatt, MD, INC.
    Medina, Ohio 44256, United States
  • Berks Hematology Oncology
    West Reading, Pennsylvania 19611, United States
  • South Carolina Oncology Associates
    Columbia, South Carolina 29210, United States
  • The West Clinic
    Memphis, Tennessee 38138, United States
  • Tenessee Oncology
    Nashville, Tennessee 37203, United States
  • Coastal Bend Cancer Center
    Corpus Christi, Texas 78404, United States
  • Center for Oncology Research and Treatment
    Dallas, Texas 75230, United States
  • Central Utah Clinic
    American Fork, Utah 84003, United States
  • Northern Utah Associates
    Ogden, Utah 84403, United States
  • Medical Oncology & Hematology Associates of Northern Virginia
    Fairfax, Virginia 22031, United States
  • Rockingham Memorial Hospital Regional Cancer Center
    Harrisonburg, Virginia 22801, United States
  • Peninsula Cancer Center
    Newport News, Virginia 23601, United States
  • Green Bay Oncologist, St Vincent Hospital
    Green Bay, Wisconsin 54301, United States
  • Oncology Alliance
    Wauwatosa, Wisconsin 53226, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2021, 11 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2008
First posted
Jun 3, 2008
Start
Mar 2008
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
May 24, 2021
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00688909
Responsible party
Sponsor
First posted
Jun 3, 2008
Start date
Mar 2008
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
May 24, 2021
Last update
Jun 9, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion